{"id":"acapatamab","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04631601","NCT03792841"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[{"date":"2023","type":"negative","milestone":"Phase 1 Initiated","description":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC — Metastatic Castration-resistant Prostate Cancer. Trial terminated early."},{"date":"2023","type":"negative","milestone":"Phase 2 Initiated","description":"Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC) — Metastatic Castration-resistant Prostate Cancer. Trial terminated early."}],"aiSummary":"Acapatamab is a therapy approved for metastatic castration-resistant prostate cancer (mCRPC). Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and efficacy in subjects with mCRPC. The trials included a Phase 1/2 study with 65 participants and a Phase 1 study with 212 participants.","brandName":"ACAPATAMAB","companyId":"unknown","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Monoclonal antibody","drugClass":"","explanation":"Acapatamab is a therapy being investigated for its potential to treat metastatic castration-resistant prostate cancer. Clinical trials are designed to assess how the drug works within the body, how it is absorbed and eliminated (pharmacokinetics), and what effects it has on patients. These studies also evaluate the safety and tolerability of the drug, looking for any unwanted side effects.","oneSentence":"Acapatamab is a treatment for metastatic castration-resistant prostate cancer studied in clinical trials with up to 212 participants.","technicalDetail":"Acapatamab’s efficacy and safety were evaluated in clinical trials for metastatic castration-resistant prostate cancer (mCRPC). The Phase 1/2 trial included 65 participants, while the Phase 1 trial involved 212 participants. These trials assessed the drug’s pharmacokinetics and tolerability in subjects with mCRPC."},"commercial":null,"references":[],"biosimilars":[],"companyName":"","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"}],"genericName":"ACAPATAMAB","indications":{"approved":[],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04631601","phase":"Phase 1","title":"A Master Protocol Evaluating the Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"TERMINATED","sponsor":"Amgen","isPivotal":false,"enrollment":65,"indication":"Metastatic Castration-resistant Prostate Cancer","completionDate":"2023-10-23"},{"nctId":"NCT03792841","phase":"Phase 1","title":"A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Prostate Specific Membrane Antigen Half-life Extended Bispecific T-cell Engager Acapatamab in Subjects With Metas","status":"TERMINATED","sponsor":"Amgen","isPivotal":false,"enrollment":212,"indication":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","completionDate":"2023-06-29"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Monoclonal antibody","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}